4E2 Stock Chart & Stats
€4.40
€0.20(4.76%)
At close: 4:00 PM EDT
€4.40
€0.20(4.76%)
Day’s Range― - ―
52-Week Range€1.80 - €6.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€308.42M
Enterprise Value€559.91M
Total Cash (Recent Filing)€217.73M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Nov 05, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding106,669,846
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-4.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.74Price Target Upside144.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.55
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash RunwayThe strengthened cash position gives Relmada substantial funding visibility for continued development, including Phase III work. A stated runway through 2029 reduces immediate financing pressure and supports execution of the pipeline without relying solely on near-term capital markets.
NDV-01 Clinical DataStrong reported 12-month Phase II efficacy and favorable safety provide a meaningful clinical foundation for advancing NDV-01 into registrational development. If replicated, these results could support differentiation and improve the program’s prospects for regulatory and commercial progress.
Regulatory PathwayFDA alignment on registration pathways gives the lead program a clearer development framework and reduces some uncertainty around the intended regulatory route. This supports more focused trial planning, with the company positioned to move toward Phase III after IND clearance.
Bears Say
Pre-commercial LossesRelmada remains dependent on clinical development rather than product revenue, while substantial losses and negative operating cash flow continue. This limits internal cash generation and means long-term funding still depends on available cash, successful programs, or future financing.
Manufacturing And CMC GatingManufacturing scale-up and CMC completion remain prerequisites for advancing NDV-01, making operational execution a direct determinant of regulatory timing. Delays in batch production or stability work could postpone Phase III initiation and defer the program’s potential value realization.
Higher Development SpendingThe sharp increase in R&D spending reflects the expanding development and manufacturing effort but also accelerates cash consumption before commercial revenues exist. Sustained higher investment raises execution and funding demands, particularly if timelines extend or additional studies are required.
Relmada Therapeutics News
4E2 FAQ
What was Relmada Therapeutics Inc’s price range in the past 12 months?
Relmada Therapeutics Inc lowest stock price was €1.80 and its highest was €6.50 in the past 12 months.
What is Relmada Therapeutics Inc’s market cap?
Relmada Therapeutics Inc’s market cap is €308.42M.
When is Relmada Therapeutics Inc’s upcoming earnings report date?
Relmada Therapeutics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 9 days.
How were Relmada Therapeutics Inc’s earnings last quarter?
Relmada Therapeutics Inc released its earnings results on Aug 06, 2026. The company reported -€0.098 earnings per share for the quarter, beating the consensus estimate of -€0.179 by €0.081.
Is Relmada Therapeutics Inc overvalued?
According to Wall Street analysts Relmada Therapeutics Inc’s price is currently Undervalued.
Does Relmada Therapeutics Inc pay dividends?
Relmada Therapeutics Inc does not currently pay dividends.
What is Relmada Therapeutics Inc’s EPS estimate?
Relmada Therapeutics Inc’s EPS estimate is -0.13.
How many shares outstanding does Relmada Therapeutics Inc have?
Relmada Therapeutics Inc has 106,669,846 shares outstanding.
What happened to Relmada Therapeutics Inc’s price movement after its last earnings report?
Relmada Therapeutics Inc reported an EPS of -€0.098 in its last earnings report, beating expectations of -€0.179. Following the earnings report the stock price went up 1.322%.
Which hedge fund is a major shareholder of Relmada Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:4E2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Relmada Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€10.74 (144.13% Upside)
€10.74 (144.13% Upside)
Blogger Sentiment
Bullish
DE:4E2 Sentiment 100%
Sector Average 67%
Sector Average 67%
Insider Transactions
Bought Shares
Worth €1.5M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
53.80%
12-Months-Change
Fundamentals
Return on Equity
-47.52%
Trailing 12-Months
Asset Growth
937.40%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
4E2 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed a constructive and execution-focused tone: Relmada reported a materially strengthened balance sheet (cash +134% YoY) with a cash runway into 2029, compelling 12-month Phase II efficacy and favorable safety for NDV-01, clear FDA-aligned registration pathways, an experienced new CBO, and engaged clinical sites. Key near-term risks center on manufacturing/CMC execution (GMP batch production and stability data), which shifted IND timing toward year-end 2026 and has increased R&D spend and operating cash use. On balance the company appears well-capitalized and positioned to advance registrational programs, but outcomes hinge on resolving manufacturing scale-up and timing.View all DE:4E2 earnings summaries4E2 Stock 12 Month Forecast
Average Price Target
€10.74
▲(144.13% Upside)